Invention Grant
- Patent Title: Pharmaceutical agent for improving autism spectrum disorder and mental disease
-
Application No.: US16964910Application Date: 2018-01-26
-
Publication No.: US11318152B2Publication Date: 2022-05-03
- Inventor: Toshihiko Yada , Yusaku Iwasaki , Shigetomo Suyama
- Applicant: MATSUTANI CHEMICAL INDUSTRY CO., LTD.
- Applicant Address: JP Itami
- Assignee: MATSUTANI CHEMICAL INDUSTRY CO., LTD.
- Current Assignee: MATSUTANI CHEMICAL INDUSTRY CO., LTD.
- Current Assignee Address: JP Itami
- Agency: Nath, Goldberg & Meyer
- Agent Joshua B. Goldberg
- International Application: PCT/JP2018/002549 WO 20180126
- International Announcement: WO2019/146082 WO 20190801
- Main IPC: A61K31/7004
- IPC: A61K31/7004 ; A61K9/00

Abstract:
An object of the present invention is to provide a novel pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect. The present invention also provides a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin in the brain. The above objects are achieved by a pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect, or a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin, which comprises D-allulose as an active ingredient.
Public/Granted literature
- US20210038621A1 PHARMACEUTICAL AGENT FOR IMPROVING AUTISM SPECTRUM DISORDER AND MENTAL DISEASE Public/Granted day:2021-02-11
Information query